S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer



Status:Active, not recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:12/12/2018
Start Date:March 2015
End Date:February 2022

Use our guide to learn which trials are right for you!

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works
and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage
IV or recurrent (has come back), epidermal growth factor receptor (EGFR) mutation positive
non-small cell lung cancer. Afatinib dimaleate may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may
block tumor growth in different ways by targeting certain cells. It is not yet known whether
afatinib dimaleate is more effective when given alone or with cetuximab in treating patients
with non-small cell lung cancer.

PRIMARY OBJECTIVES:

I. To evaluate if there is sufficient evidence to continue to the phase III component by
comparing progression-free survival (PFS) between patients randomized to afatinib (afatinib
dimaleate) in combination with cetuximab versus afatinib alone in the first-line treatment of
patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). (Phase II) II. To
determine the efficacy of the combination of afatinib and cetuximab compared to afatinib
alone as measured by overall survival (OS) in the first-line treatment of patients with
advanced EGFR-mutant NSCLC. (Phase III)

SECONDARY OBJECTIVES:

I. To evaluate the overall response rate (confirmed and unconfirmed, complete and partial
responses) in the subset of patients with measurable disease treated with afatinib plus
cetuximab compared to afatinib alone.

II. To assess the safety of each treatment arm when used in the first-line setting.

III. To compare time to treatment failure and time to treatment discontinuation between
randomized to afatinib in combination with cetuximab versus afatinib alone.

TERTIARY OBJECTIVES:

I. To investigate the molecular mechanisms that confer benefit from afatinib and afatinib
plus cetuximab by evaluating whether the presence of de novo EGFR T790M mutation or other
molecular alterations in the pre-treatment tumor influence the clinical outcomes.

II. To quantitatively assess whether the ratio of sensitizing EGFR (EGFRs) mutation to EGFR
T790M influences outcome and is altered during treatment.

III. To evaluate the frequency of known mechanisms of resistance to EGFR-directed therapies
in the context of afatinib plus cetuximab and afatinib alone treatment.

IV. To identify potential novel predictors of benefit to afatinib plus cetuximab.

V. To identify potential new mechanisms of resistance to EGFR-directed therapies.

VI. To establish patient-derived xenografts (PDXs) from a subset of patients by re-biopsy at
the time of progressive disease for drug testing and genomic analysis.

VII. To assess whether circulating tumor markers can be used as indicators of sensitivity and
resistance to afatinib plus cetuximab and afatinib alone.

VIII. To determine whether the levels of EGFR protein by immunohistochemistry predict for
benefit to afatinib plus cetuximab and afatinib alone.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive afatinib dimaleate orally (PO) once daily (QD) on days 1-28 and
cetuximab intravenously (IV) over 2 hours on days 1 and 15. Courses repeat every 28 days in
the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 3 years.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed stage IV (American Joint
Committee on Cancer [AJCC] 7th Edition) or recurrent non-small cell lung cancer
(NSCLC)

- Patients must have documented presence of an EGFR exon 19 deltion or exon 21 (L858R)
substitution mutation; T790M mutation or other molecular abnormality will be allowed
as long as it accompanies one of the mutations listed above; EGFR testing must be
performed using a Food and Drug Administration (FDA)-approved test or in a Clinical
Laboratory Improvement Amendments (CLIA)-certified laboratory.

- Patients must have tissue available and must agree to submission of tissue and blood;
one to two paraffin-embedded tissue blocks or 15-20 unstained slides are requested (a
minimum of 12 slides is required); cytology (i.e. fine-needle aspirations, pleural
effusion specimens) is acceptable if a cell block or sufficient unstained slides are
available; tumor material must be reviewed by a local pathologist who must confirm
that at least 100 viable tumor cells are present in the sample and sign the S1403
Pathology Review Form; patients must also be willing to submit blood samples for
correlative research at baseline, during treatment and at progression

- Patients enrolled at sites participating in the Repeat Biopsy Study must agree to
submission of tissue obtained by a repeat biopsy performed at the time of disease
progression

- Patients must not have received any prior systemic anticancer therapy for advanced or
metastatic disease including chemotherapy or EGFR tyrosine kinase inhibitor therapy
(including gefitinib, erlotinib, afatinib, or any experimental EGFR tyrosine kinase
inhibitors [TKI] agents); prior chemotherapy for non-metastatic disease (i.e. adjuvant
therapy or concurrent chemo-radiotherapy) is allowed as long as > 12 months has passed
since completion of therapy; adjuvant EGFR-directed therapy is not allowed; local
therapy (i.e. palliative radiotherapy) is allowed as long as a period of 7 days has
passed since the last dose was received and the patient has recovered from any
associated toxicity at the time of registration

- Patients may have measurable or non-measurable disease documented by computed
tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to
registration; the CT from a combined positron emission tomography (PET)/CT may be used
only if it is of diagnostic quality; laboratory parameters are not acceptable as the
only evidence of disease; in order to qualify as measurable, measurable disease must
be outside previous radiation field; all disease must be assessed and documented on
the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors
[RECIST] 1.1)

- Patients must have a CT or MRI scan of the brain to evaluate for central nervous
system (CNS) disease within 42 days prior to registration; patient must not have
symptomatic brain metastases or evidence of leptomeningeal carcinomatosis; patients
with asymptomatic brain metastases are eligible if off of steroids for at least 7 days
prior to registration without development of symptoms

- Patients must not have any known clinically active interstitial lung disease

- Absolute neutrophil count (ANC) >= 1,500/mcL

- Platelets >= 75,000/mcL

- Hemoglobin >= 9 g/dL

- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or
=< 5 x IULN for patients with known liver metastases)

- Serum creatinine =< 1.5 x IULN OR measured or calculated creatinine clearance >= 60
mL/min

- Patients must not have significant gastrointestinal disorders with diarrhea as a major
symptom (e.g. Crohn's disease, malabsorption, etc)

- Patients must be able to swallow medication by oral route

- Patients must not have a history of clinically relevant cardiovascular abnormalities
such as uncontrolled hypertension, congestive heart failure New York Heart Association
(NYHA) classification of 3, unstable angina or poorly controlled arrhythmia or
myocardial infarction within 6 months prior to registration; if clinically indicated,
echocardiogram or multigated acquisition (MUGA) must be performed and cardiac ejection
fraction must be >= 50%

- Patients must not have had major surgery within 28 days prior to registration or be
scheduled for surgery during the projected course of protocol treatment; tumor biopsy
is allowed

- Patients must not have a known history of active hepatitis B infection (defined as
presence of hepatitis B surface antigen [Hep B sAg] and/ or Hep B deoxyribonucleic
acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C]
ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) seropositive

- Patients must not have any other concomitant serious illness or organ system
dysfunction which in the opinion of the investigator would either compromise patient
safety or interfere with the evaluation of the safety of the study drug

- Patients must not be planning to receive any other investigational agents during the
course of protocol treatment

- Patients must not have a history of allergic reactions attributed to compounds of
similar chemical or biologic composition to afatinib and/or cetuximab

- Prestudy history and physical must be obtained with 28 days prior to registration

- Patients must have Zubrod performance status of 0 - 2

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for three years

- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures

- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines

- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system
We found this trial at
639
sites
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Ian Rabinowitz
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
?
mi
from
Augusta, ME
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
701 Doctors Dr
Kinston, North Carolina 28504
(252) 559-2200
Principal Investigator: Peter R. Watson
Phone: 252-559-2200
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
?
mi
from
Kinston, NC
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
777 Hemlock Street
Macon, Georgia 31201
(478) 633-1000
Principal Investigator: Frederick M. Schnell
Phone: 478-633-1226
Medical Center of Central Georgia Navicent Health is a designated Level I Trauma Center and...
?
mi
from
Macon, GA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Anand B. Karnad
Phone: 518-489-3612
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
1 Akron General Ave
Akron, Ohio 44307
(330) 344-6000
Principal Investigator: Esther H. Rehmus
Phone: 330-344-6348
Akron General Medical Center It
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Ian Rabinowitz
Phone: 505-925-0366
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Ian Rabinowitz
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Ames, IA
Click here to add this to my saved trials
1111 Duff Ave
Ames, Iowa 50010
(866) 972-5477
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
McFarland Clinic PC-William R Bliss Cancer Center The William R. Bliss Cancer Center at Mary...
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Han A. Koh
Phone: 626-564-3455
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Gregory P. Kalemkerian
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 877-405-6866
?
mi
from
Antigo, WI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Yujie Zhao
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: David R. Gandara
Phone: 916-734-3089
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Han A. Koh
Phone: 626-564-3455
?
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Bartlett, Tennessee 38133
Principal Investigator: Raymond U. Osarogiagbon
Phone: 901-448-3303
?
mi
from
Bartlett, TN
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: James P. Ohr
Phone: 724-773-7616
?
mi
from
Beaver, PA
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-395-8115
?
mi
from
Beavercreek, OH
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Han A. Koh
Phone: 626-564-3455
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
1300 Anne Street NW
Bemidji, Minnesota 56601
(218) 751-5430
Principal Investigator: Preston D. Steen
Phone: 712-252-0088
Sanford Clinic North-Bemidgi Sanford Health is a voluntary, not-for-profit health care organization. Through its entities,...
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Bettendorf, Iowa 52722
Principal Investigator: David M. Spector
Phone: 309-779-4200
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Beverly, Massachusetts 01915
Principal Investigator: Angus P. McIntyre
Phone: 978-283-4000
?
mi
from
Beverly, MA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 712-252-0088
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Boone, IA
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 888-221-4849
?
mi
from
Branson, MO
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
?
mi
from
Brewer, ME
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bryan, TX
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Burien, WA
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Burlingame, CA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Krishna S. Gunturu
Phone: 781-744-8027
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Dhimant R. Patel
Phone: 715-735-6523
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Cameron Park, CA
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Canton, MI
Click here to add this to my saved trials
Canton, Ohio 44708
Principal Investigator: Mitchell Haut
Phone: 888-293-4673
?
mi
from
Canton, OH
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: James L. Wade
Phone: 309-243-3605
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: James L. Wade
Phone: 309-243-3605
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Caro, MI
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Chadds Ford, Pennsylvania 19317
?
mi
from
Chadds Ford, PA
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
(620) 431-7580
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Chanute, KS
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 614-488-2745
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
?
mi
from
Chillicothe, OH
Click here to add this to my saved trials
12961 27th Ave
Chippewa Falls, Wisconsin 54729
715-738-3700
Principal Investigator: Bilal H. Naqvi
Phone: 715-717-3956
Marshfield Clinic - Chippewa Center The 15,000 square foot Lake Hallie Center provides urgent care...
?
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45230
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45211
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials